These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27628221)

  • 21. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
    Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
    Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction.
    Lund LH; Benson L; Dahlström U; Edner M; Friberg L
    JAMA; 2014 Nov; 312(19):2008-18. PubMed ID: 25399276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.
    Cohen Solal A; Leurs I; Assyag P; Beauvais F; Clerson P; Contre C; Thebaut JF; Genoun M;
    Arch Cardiovasc Dis; 2012; 105(6-7):355-65. PubMed ID: 22800720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
    Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of hyponatremia among ambulatory patients with heart failure and preserved and reduced ejection fractions.
    Bavishi C; Ather S; Bambhroliya A; Jneid H; Virani SS; Bozkurt B; Deswal A
    Am J Cardiol; 2014 Jun; 113(11):1834-8. PubMed ID: 24837261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker.
    Furuhashi M; Moniwa N; Mita T; Fuseya T; Ishimura S; Ohno K; Shibata S; Tanaka M; Watanabe Y; Akasaka H; Ohnishi H; Yoshida H; Takizawa H; Saitoh S; Ura N; Shimamoto K; Miura T
    Am J Hypertens; 2015 Jan; 28(1):15-21. PubMed ID: 24842388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction.
    Lund LH; Benson L; Dahlström U; Edner M
    JAMA; 2012 Nov; 308(20):2108-17. PubMed ID: 23188027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population.
    Cheng RK; Cox M; Neely ML; Heidenreich PA; Bhatt DL; Eapen ZJ; Hernandez AF; Butler J; Yancy CW; Fonarow GC
    Am Heart J; 2014 Nov; 168(5):721-30. PubMed ID: 25440801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center.
    Bress AP; King JB; Brixner D; Kielhorn A; Patel HK; Maya J; Lee VC; Biskupiak J; Munger M
    Pharmacotherapy; 2016 Feb; 36(2):174-86. PubMed ID: 26841333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coronary artery disease and 10-year outcome after hospital admission for heart failure with preserved and with reduced ejection fraction.
    Rusinaru D; Houpe D; Szymanski C; Lévy F; Maréchaux S; Tribouilloy C
    Eur J Heart Fail; 2014 Sep; 16(9):967-76. PubMed ID: 25111982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction.
    Lok DJ; Klip IT; Voors AA; Lok SI; Bruggink-André de la Porte PW; Hillege HL; Jaarsma T; van Veldhuisen DJ; van der Meer P
    Eur J Heart Fail; 2014 Sep; 16(9):958-66. PubMed ID: 25082741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
    Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unfavourable outcomes in patients with heart failure with higher preserved left ventricular ejection fraction.
    Ohte N; Kikuchi S; Iwahashi N; Kinugasa Y; Dohi K; Takase H; Masai K; Inoue K; Okumura T; Hachiya K; Kitada S; Seo Y;
    Eur Heart J Cardiovasc Imaging; 2023 Feb; 24(3):293-300. PubMed ID: 36464890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction.
    Melenovsky V; Hwang SJ; Redfield MM; Zakeri R; Lin G; Borlaug BA
    Circ Heart Fail; 2015 Mar; 8(2):295-303. PubMed ID: 25593126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy.
    Schwartzenberg S; Redfield MM; From AM; Sorajja P; Nishimura RA; Borlaug BA
    J Am Coll Cardiol; 2012 Jan; 59(5):442-51. PubMed ID: 22281246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction.
    Sanders-van Wijk S; van Empel V; Davarzani N; Maeder MT; Handschin R; Pfisterer ME; Brunner-La Rocca HP;
    Eur J Heart Fail; 2015 Oct; 17(10):1006-14. PubMed ID: 26472682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of estimated plasma volume reduction on renal function for acute heart failure differs between patients with preserved and reduced ejection fraction.
    Takei M; Kohsaka S; Shiraishi Y; Goda A; Izumi Y; Yagawa M; Mizuno A; Sawano M; Inohara T; Kohno T; Fukuda K; Yoshikawa T;
    Circ Heart Fail; 2015 May; 8(3):527-32. PubMed ID: 25737498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myocardial contractile dysfunction associated with increased 3-month and 1-year mortality in hospitalized patients with heart failure and preserved ejection fraction.
    Zhong L; Ng KK; Sim LL; Allen JC; Lau YH; Sim DK; Lee RK; Poh KK; Chua TS; Kassab GS; Kwok BW; Tan RS
    Int J Cardiol; 2013 Oct; 168(3):1975-83. PubMed ID: 23336957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.